Efficacy and safety of the sodium-glucose co-transporter-2 inhibitor empagliflozin in elderly Japanese adults (≥65 years) with type 2 diabetes: A randomized, double-blind, placebo-controlled, 52-week clinical trial (EMPA-ELDERLY).
Daisuke YabeKosuke ShikiGosuke HommaThomas MeinickeYuji OguraYutaka Seinonull nullPublished in: Diabetes, obesity & metabolism (2023)
Empagliflozin improved glucose control and reduced body weight without compromising muscle mass or strength in elderly adults with T2D in this trial.